1915 related articles for article (PubMed ID: 26308912)
21. Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials.
Chow R; Tsao M; Chiu L; Popovic M; Milakovic M; Lam H; DeAngelis C
Ann Palliat Med; 2018 Apr; 7(2):221-233. PubMed ID: 29764184
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study.
Chang J; Chen G; Wang D; Wang G; Lu S; Feng J; Li W; Li P; Lanzarotti C; Chessari S; Zhang L
Cancer Med; 2020 Jul; 9(14):5134-5142. PubMed ID: 32472742
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
A Mahrous M; A El-Azab G; A Tawfik H
Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
[TBL] [Abstract][Full Text] [Related]
24. Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients.
Navari RM
Paediatr Drugs; 2017 Jun; 19(3):213-222. PubMed ID: 28447301
[TBL] [Abstract][Full Text] [Related]
25. Comparison of two different intravenous serotonin antagonists used for chemotherapy-induced nausea and vomiting prophylaxis in patients treated with moderately emetogenic risk regimens: A retrospective analysis from a large academic medical center.
Gamble M; Carroll E; Wright GC; Glode AE
J Oncol Pharm Pract; 2020 Dec; 26(8):1964-1969. PubMed ID: 32633661
[TBL] [Abstract][Full Text] [Related]
26. State of the Art Antiemetic Therapy for Cancer Patients.
Lau TK; Yip CH; Yeo W
Curr Oncol Rep; 2016 Jan; 18(1):2. PubMed ID: 26694923
[TBL] [Abstract][Full Text] [Related]
27. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.
Navari RM
Future Oncol; 2006 Oct; 2(5):591-602. PubMed ID: 17026451
[TBL] [Abstract][Full Text] [Related]
28. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study.
Mizukami N; Yamauchi M; Koike K; Watanabe A; Ichihara K; Masumori N; Yamakage M
J Pain Symptom Manage; 2014 Mar; 47(3):542-50. PubMed ID: 23856100
[TBL] [Abstract][Full Text] [Related]
29. The current status of the use of palonosetron.
Navari R
Expert Opin Pharmacother; 2013 Jul; 14(10):1281-4. PubMed ID: 23647207
[TBL] [Abstract][Full Text] [Related]
30. [Guidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting].
Durand JP; Madelaine I; Scotté F
Bull Cancer; 2009 Oct; 96(10):951-60. PubMed ID: 19734117
[TBL] [Abstract][Full Text] [Related]
31. Rolapitant for the prevention of delayed nausea and vomiting over initial and repeat courses of emetogenic chemotherapy.
Rapoport B; van Eeden R; Smit T
Expert Rev Clin Pharmacol; 2017 Jan; 10(1):17-29. PubMed ID: 27894202
[TBL] [Abstract][Full Text] [Related]
32. Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV).
Navari RM
Drug Des Devel Ther; 2015; 9():155-61. PubMed ID: 25552904
[TBL] [Abstract][Full Text] [Related]
33. New and emerging therapeutic options for the management of chemotherapy-induced nausea and vomiting.
Schwartzberg LS; Rugo HS; Aapro MS
Clin Adv Hematol Oncol; 2015 Mar; 13(3 Suppl 3):3-13, 1; quiz 2 p following 14. PubMed ID: 25856052
[TBL] [Abstract][Full Text] [Related]
34. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
35. Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents.
Navari RM
Drugs; 2013 Mar; 73(3):249-62. PubMed ID: 23404093
[TBL] [Abstract][Full Text] [Related]
36. NEPA as antiemetic prophylaxis after failure of 5HT
Valerio MR; Gebbia V; Borsellino N; Vecchia M; Serretta V; Pardo S; Cipolla C; Galanti D
J Oncol Pharm Pract; 2021 Apr; 27(3):609-613. PubMed ID: 32507099
[TBL] [Abstract][Full Text] [Related]
37. Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
Navari RM
Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1577-86. PubMed ID: 19929251
[TBL] [Abstract][Full Text] [Related]
38. [Medical treatment of chemotherapy-induced nausea and vomiting].
Herrstedt J
Ugeskr Laeger; 2007 Feb; 169(9):799-805. PubMed ID: 17355844
[TBL] [Abstract][Full Text] [Related]
39. Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.
Aapro M; Hesketh PJ; Jordan K; Gralla RJ; Rossi G; Rizzi G; Palmas M
Oncologist; 2016 Apr; 21(4):494-502. PubMed ID: 27000465
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis.
Yokoe T; Hayashida T; Nagayama A; Nakashoji A; Maeda H; Seki T; Takahashi M; Takano T; Abe T; Kitagawa Y
Oncologist; 2019 Jun; 24(6):e347-e357. PubMed ID: 30333194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
